American Journal of Kidney Diseases
Volume 54, Issue 3 , Pages 498-510 , September 2009

Anemia Management and Association of Race With Mortality and Hospitalization in a Large Not-for-Profit Dialysis Organization

  • Karen S. Servilla, MD

      Affiliations

    • Nephrology Section, New Mexico Veterans Affairs Health Care System, Albuquerque, NM
    • Dialysis Clinic Inc Quality Management Division, Albuquerque, NM
    • University of New Mexico Health Sciences Center, Albuquerque, NM
    • ,
  • Ajay K. Singh, MD

      Affiliations

    • Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
    • ,
  • William C. Hunt, MA

      Affiliations

    • Dialysis Clinic Inc Quality Management Division, Albuquerque, NM
    • ,
  • Antonia M. Harford, MD

      Affiliations

    • University of New Mexico Health Sciences Center, Albuquerque, NM
    • ,
  • Dana Miskulin, MD, MS

      Affiliations

    • Tufts Medical Center, Boston, MA
    • ,
  • Klemens B. Meyer, MD

      Affiliations

    • Tufts Medical Center, Boston, MA
    • ,
  • Edward J. Bedrick, PhD

      Affiliations

    • Department of Mathematics and Statistics, University of New Mexico, Albuquerque, NM
    • ,
  • Mark R. Rohrscheib, MD

      Affiliations

    • University of New Mexico Health Sciences Center, Albuquerque, NM
    • ,
  • Antonios H. Tzamaloukas, MD

      Affiliations

    • Nephrology Section, New Mexico Veterans Affairs Health Care System, Albuquerque, NM
    • ,
  • H. Keith Johnson, MD

      Affiliations

    • Dialysis Clinic Inc, Nashville, TN
    • ,
  • Philip G. Zager, MD

      Affiliations

    • Dialysis Clinic Inc Quality Management Division, Albuquerque, NM
    • University of New Mexico Health Sciences Center, Albuquerque, NM
    • Corresponding Author InformationAddress correspondence to Philip G. Zager, MD, University of New Mexico, Department of Internal Medicine, 1500 Indian School Rd NE, Ste 200, Albuquerque NM 87102

Received 7 November 2008 ,Accepted 14 May 2009.

References 

  1. Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. Semin Nephrol. 1989;9:16–21
  2. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94–111
  3. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease (Results of a phase III multicenter clinical trial). Ann Intern Med. 1989;111:992–1000
  4. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int. 2004;65:622–633
  5. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908–1914
  6. Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int. 2005;68:1432–1438
  7. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agents and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  8. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney Int. 2005;68:2323;-2230
  9. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10:1309–1316
  10. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866–876
  11. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  12. Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  13. Drueke TB, Locatelli F, Clyne N, et al. CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  14. van Manen JG, van Dijk PC, Stel VS, et al. Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant. 2007;22:187–195
  15. Adamson JW. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: The many faces of inflammation. Adv Chronic Kidney Dis. 2009;16:76–82
  16. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205–1210
  17. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  18. Lacson E, Rogus J, Teng M, Lazarus JM, Hakim RM. The association of race with erythropoietin dose in patients on long-term hemodialysis. Am J Kidney Dis. 2008;52:1104–1114
  19. Owen WJ. Racial differences in incidence, outcome, and quality of life for African-Americans on hemodialysis. Blood Purif. 1996;14:278–285
  20. Price DA, Owen WJ. African-Americans on maintenance dialysis: A review of racial differences in incidence, treatment, and survival. Adv Ren Replace Ther. 1997;4:3–12
  21. Robinson BM, Joffe MM, Pisoni RL, Port FK, Feldman HI. Revisiting survival differences by race and ethnicity among hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol. 2006;17:2910–2918
  22. Sargent JA, Gotch FA. Mathematic modeling of dialysis therapy. Kidney Int Suppl. 1980;18:S2–S10
  23. Weiner DE, Miskulin DC, Seefeld K, et al. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007;18:3184–3191
  24. Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int. 2004;66:1193–1198
  25. Fletes S, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001;37:743–749
  26. Horl WH. Should we still use iron dextran in hemodialysis patients. Am J Kidney Dis. 2001;37:859–861
  27. Kelly PJ, Lim L. Survival analysis for recurrent event data: An application to childhood infectious diseases. Stat Med. 2000;19:13–33
  28. Fink JC, Hsu VD, Zhan M, et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol. 2007;18:646–653
  29. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2005 Annual Data report. Am J Kidney Dis. 2005;45(suppl 1):S41–S56
  30. Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008;51:62–70
  31. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1077–1083
  32. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32:107–114
  33. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ES) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant. 2009;24:919–925
  34. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;47:139–148
  35. Menon V, Wang X, Greene T, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis. 2003;42:44–52
  36. Owen WJ, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329:1001–1006
  37. Feldman H, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623–1632
  38. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–3080
  39. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727–736
  40. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis. 2004;43:671–784
  41. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis. 2007;49:A6–A296
  42. Kaufman JS. Racial differences in erythropoietin responsiveness. Am J Kidney Dis. 2008;52:1035–1038
  43. Beutler E, West C. Hematologic differences between African-Americans and whites: The roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood. 2005;106:740–745
  44. Robins JM, Hernan MA, Rotnitzky A. Effect modification by time-varying covariates. Am J Epidemiol. 2007;166:994–1002
  45. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–1886
  46. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–1892
  47. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research (Interpreting the evidence: Choosing between randomised and non-randomised studies). BMJ. 1999;319:312–315

 Originally published online as doi: 10.1053/j.ajkd.2009.05.007 on July 24, 2009.

 Because the Editor-in-Chief and Deputy Editor recused themselves from consideration of this manuscript, the peer-review and decision-making processes were handled entirely by a Co-Editor (James S. Kaufman, MD, Renal Section, Veterans Affairs Boston Healthcare System and Boston University School of Medicine, Boston, MA) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)00772-0

doi: 10.1053/j.ajkd.2009.05.007

American Journal of Kidney Diseases
Volume 54, Issue 3 , Pages 498-510 , September 2009

Article Tools

* Image Usage & Resolution